Abstract: When a rebuild process is to be performed for a disk array, a power supply is checked. In this case, when a battery is used, the rebuild process is inhibited in accordance with a user setting. The remaining capacity of the battery is checked to change the effective rate of the rebuild process on the basis of the remaining capacity. A consistency check is also performed in the same manner.

Abstract: According to one embodiment, a disk array device capable of utilizing redundant areas, which are a part of areas on disk devices constituting a disk array and are not incorporated into the disk array, as areas of stand-alone disk devices other than the disk array, includes a determining unit configured to determine whether or not the redundant areas are in use as the areas of the stand-alone disk devices, and a disk array construction unit configured to make the determining unit determines whether or not the redundant areas are in use as the areas of the stand-alone disk devices in installing the redundant areas to construct a new disk array, and to re-arrange data recorded in the redundant areas onto the new disk array, when it is determined that the redundant areas are in use as the areas of the stand-alone disk devices.

Abstract: When a rebuild process is to be performed for a disk array, a power supply is checked. In this case, when a battery is used, the rebuild process is inhibited in accordance with a user setting. The remaining capacity of the battery is checked to change the effective rate of the rebuild process on the basis of the remaining capacity. A consistency check is also performed in the same manner.

Abstract: An N-acylamino acid derivative of the formula: ##STR1##

Abstract: An N-acylamino acid derivative of the formula: ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.4 and R.sup.6 is hydrogen lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containing from to 4 hetero atoms; each of R.sup.3 and R.sup.5 is hydrogen or lower alkyl; A is --CH(OH)--(CH.sub.2).sub.q R.sup.7 wherein R.sup.7 is hydrogen, lower alkyl, cycloalkyl, cyloalkylalkyl, aryl, aralkyl, a monocyclic or bicyclic heterocyclic group containing from to 4 hereto atoms or --E--R.sup.10 wherein E is --S(O).sub.i -- wherein i is 0, 1 or 2, oxygen, --NR.sup.11 -- wherein R.sup.11 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, or ##STR2## wherein each of R.sup.12 and R.sup.13 is hydrogen, lower alkyl cycloalkyl, cycloalkylalkyl, aryl or aralkyl, and R.sup.10 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms provided that when R.sup.

Abstract: An N-acylamino acid derivative of the formula: ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.4 and R.sup.6 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms; each of R.sup.3 and R.sup.5 is hydrogen or lower alkyl; A is --CH(OH)--(CH.sub.2).sub.q R.sup.7 wherein R.sup.7 is hydrogen, lower alkyl, cycloalkyl, cyloalkylalkyl, aryl, aralkyl, a-monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms or --E--R.sup.10 wherein E is --S(O).sub.i -- wherein i is 0, 1 or 2, oxygen, --NR.sup.11 -- wherein R.sup.11 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, or ##STR2## wherein each of R.sup.12 and R.sup.13 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, and R.sup.10 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or a monocyclic or bicyclic heterocyclic group containing from 1 to 4 hetero atoms provided that when R.sup.

Abstract: An N-acylamino acid derivative of the formula: ##STR1## wherein the substituents are herein defined, or a salt thereof, which is useful as hypotensive drugs.

Abstract: An N-acylamino acid derivative of the formula: ##STR1## wherein the substituents are herein defined or a salt thereof, which is useful as hypotensive drugs.

Abstract: A 5-substituted amino-4-hydroxy-pentenoic acid or its salt represented by the formula: ##STR1## wherein each of R.sup.1 and R.sup.2 which may be the same or different is a hydrogen atom, a lower alkyl group, an aralkyl group, a lower alkoxycarbonyl group, an aryloxycarbonyl group, an aralkyloxycarbonyl group or a lower alkanoyl group which may be substituted by from one to three substituents selected from the group consisting of an amino group, a hydroxyl group, a carboxyl group, an aryloxy group, an aralkyloxycarbonylamino group, a lower alkoxycarbonylamino group and a ##STR2## group (wherein each of X.sup.1 and X.sup.2 which may be the same or different is a hydrogen atom, a lower alkyl group, an aryl group or an aralkyl group, or X.sup.1 and X.sup.

Abstract: A 5-substituted amino-4-hydroxy-pentanoic acid derivative having the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an N-protecting group, R.sup.2, R.sup.3 and R.sup.5 may be any of a variety of groups including the side chains of amino acid residues, R.sup.4 is a hydrogen atom or a lower alkyl group, R.sup.6 is a group which is substituted by one or two hydroxyl groups, and R.sup.7 is any of a variety of groups, including a hydroxyl group, which compounds are renin inhibitors useful as hypotensive drugs, are disclosed.